135 related articles for article (PubMed ID: 31364073)
1. Pharmacokinetics of Polymyxins in Animals.
Marchand S; Grégoire N; Couet W
Adv Exp Med Biol; 2019; 1145():89-103. PubMed ID: 31364073
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Polymyxins: Implications for Therapeutic Use.
Nation RL; Forrest A
Adv Exp Med Biol; 2019; 1145():219-249. PubMed ID: 31364081
[TBL] [Abstract][Full Text] [Related]
3. Bioanalysis and Stability of Polymyxins.
Milne RW
Adv Exp Med Biol; 2019; 1145():73-87. PubMed ID: 31364072
[TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?
Zavascki AP; Nation RL
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27993859
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the Individual Major Components of Polymyxin B and Colistin in Rats.
Sivanesan S; Roberts K; Wang J; Chea SE; Thompson PE; Li J; Nation RL; Velkov T
J Nat Prod; 2017 Jan; 80(1):225-229. PubMed ID: 28080060
[TBL] [Abstract][Full Text] [Related]
7. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.
Bergen PJ; Bulman ZP; Saju S; Bulitta JB; Landersdorfer C; Forrest A; Li J; Nation RL; Tsuji BT
Pharmacotherapy; 2015 Jan; 35(1):34-42. PubMed ID: 25630411
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
[TBL] [Abstract][Full Text] [Related]
9. Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.
Landersdorfer CB; Nguyen TH; Lieu LT; Nguyen G; Bischof RJ; Meeusen EN; Li J; Nation RL; McIntosh MP
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821445
[TBL] [Abstract][Full Text] [Related]
10. Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.
Zavascki AP
Expert Rev Anti Infect Ther; 2014 May; 12(5):531-3. PubMed ID: 24666285
[TBL] [Abstract][Full Text] [Related]
11. A Population WB-PBPK Model of Colistin and its Prodrug CMS in Pigs: Focus on the Renal Distribution and Excretion.
Viel A; Henri J; Bouchène S; Laroche J; Rolland JG; Manceau J; Laurentie M; Couet W; Grégoire N
Pharm Res; 2018 Mar; 35(5):92. PubMed ID: 29532176
[TBL] [Abstract][Full Text] [Related]
12. In vitro Pharmacodynamics and PK/PD in Animals.
Lee W; Cai Y; Lim TP; Teo J; Chua SC; Kwa AL
Adv Exp Med Biol; 2019; 1145():105-116. PubMed ID: 31364074
[TBL] [Abstract][Full Text] [Related]
13. Colistin and polymyxin B: peas in a pod, or chalk and cheese?
Nation RL; Velkov T; Li J
Clin Infect Dis; 2014 Jul; 59(1):88-94. PubMed ID: 24700659
[TBL] [Abstract][Full Text] [Related]
14. Polymyxin B versus colistin: an update.
Cai Y; Lee W; Kwa AL
Expert Rev Anti Infect Ther; 2015; 13(12):1481-97. PubMed ID: 26488563
[TBL] [Abstract][Full Text] [Related]
15. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
[TBL] [Abstract][Full Text] [Related]
16. A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat.
Bouchene S; Marchand S; Couet W; Friberg LE; Gobin P; Lamarche I; Grégoire N; Björkman S; Karlsson MO
Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):407-422. PubMed ID: 29665289
[TBL] [Abstract][Full Text] [Related]
17. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.
Li J; Milne RW; Nation RL; Turnidge JD; Smeaton TC; Coulthard K
J Antimicrob Chemother; 2004 May; 53(5):837-40. PubMed ID: 15044428
[TBL] [Abstract][Full Text] [Related]
19. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
Kassamali Z; Danziger L
Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
[TBL] [Abstract][Full Text] [Related]
20. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
Kassamali Z; Jain R; Danziger LH
Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
